Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma

Urologia Internationalis

Volumn 56, Issue , 1996, Pages 18-22

  Fornara, P ^a   Jocham, D ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

3 month depot formulation; Advanced prostate cancer; Leuprorelin acetate

Indexed keywords

ANDROSTANOLONE; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; EDEMA; ERYTHEMA; FOLLITROPIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; IMPOTENCE; INJECTION PAIN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; METABOLIC DISORDER; MICTURITION DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN ALLERGY; SLEEP DISORDER; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; SWEATING; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; VASCULAR DISEASE; WEIGHT GAIN;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; HUMANS; LEUPROLIDE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0029969452     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282864     Document Type: Article

References (25)

1. Allhoff E, Liedke S, de Riese W. et al: Wandel in Diagnostik und Verlaufskontrolle des Prostatakarzinoms; in Helpap B. Senge Th, Vahlen-sieck W (eds): Prostataerkrankungen. Prostata-Workshop, Frankfurt am Main 1988. Frankfurt am Main, pmi Verlag. 1988, pp 259-267.
2. Dhom G, Bonkhoff H: Epidemiologische und morphologische Aspekte des Prostatakarzinoms. in Jakse G, Wolff JM (eds): Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. Berlin, Springer, 1992, pp 3-16.
3. Veterans Administration Cooperative Urological Research Group (VACURG): Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124:1011.
4. Geller J: Basis for hormonal management of advanced prostate cancer. Cancer 1993; 71 (suppl 3): 1039-1045.
5. Labrie F, Dupont A, Belanger A, et al: Flutam-ide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J Drug Dev 1987; 1 (suppl 1): 34.
6. Rohl HF, Beukc HP: Effect of orchiectomy on scrum concentrations of testosterone and dihy-drotestosteronc in patients with prostatic cancer. Scand J Urol Nephrol 1992;26:11-14.
7. Scott WW, Menon M, Walsh PC: Hormone therapy of prostatic cancer. Cancer 1990;45: 1929.
8. Verres R, Lopau I, Schaaf H, Lanszuz K: Subscapular orchiectomy vs. LHRH analog. Preference of therapy and mental state in patients with advanced prostate carcinoma. Urologe [B] 1994:34:214-218.
9. Young HH, Kent JR: Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol 1968;99:78.
10. Altwein JE: Das fortgeschrittene Prostatakarzinom: Probleme der Hormonotherapie; in Altwein JE, Bartsch G (eds): Therapie des fortgeschrittenen Prostatakarzinoms. Internationales Symposium. 1988. Frankfurt am Main, pmi Verlag, 1989, pp 1-31.
11. Oesterling JE, Chan DW, Epstein J. et al: Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988:139:766.
12. Ruttqvist LE, Wilking N: Analogues of LHRH vs. orchiectomy: Comparison of economic costs for castration in advanced prostate cancer. Br J Cancer 1992;65:927-929.
13. Akaza H, Aso Y, Koiso Kand theTAP-144-SR Study Group: Leuprorelin acetate depot: Results of a multicentre Japanese trial. J Int Med Res 1990; 18(suppl 1):90-102.
14. Bischoff W: German leuprorelin study group: 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: Preliminary report. J Int Med Res 1990; 18(suppl 1): 103-113.
15. Calais da Silva F: Quality of life in prostatic carcinoma. Eur Urol 1993;24(suppl 2): 113-117.
16. Crawford ED: Derzeitige Konzepte in der Behandlung des fortgeschrittenen Prostatakarzinoms und Zwischenbericht über die Phasc-lII Studie Leuprorelin plus Placebo vs. Leuprorelin plus Flutamid der South West Oncology Group 8494: in Altwein JE. Bartsch G (eds): Therapie des fortgeschrittenen Prostatakarzinoms. Internationales Symposium. 1988. Frankfurt am Main, pmi Verlag. 1989: pp 1-31.
17. Eisenberger MA, et al: Gonadotropin hormone-releasing hormone analogues: A new therapeutic approach for prostatic carcinoma. J Clin Oncol 1986;43:414-424.
18. Fornara P: Multicenter-Studie mit Enantone® Monats-Depot - Langzeitverlaufskontrollc; in Jakse G, Wolff JM (eds): Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. Berlin. Springer, 1992, pp91-99.
19. O’Brien A, Graininger R, Butler MR: Experience with leuprorelin acetate as a depot formulation for prostate cancer in a long-term follow-up study; in Jakse G. Wolff JM (eds): Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. Berlin, Springer, 1992, pp 73-90.
20. Hübner R: Worin besteht die galenische Innovation bei Enantone® Monats-Dcpot? In Jakse G. Wolff JM (eds): Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. Berlin, Springer. 1992, pp 90-99.
21. Okada H, Doken Y, Ogawa Y, Toguchi H: Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs. Pharm Res 1994:11: 1199-1203.
22. Mazzei T, et al: Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. J Int Med Res 1990:18(suppl 1):4256.
23. Giuliani L, Pescatore D, Gilberti C. et al: Treatment of advanced prostatic carcinoma with cyprotcronc acetate and orchiectomy. 5-vear follow-up. EurUrol 1980:6:145-148.
24. Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer; in Devita VT, Heilman S, Rosenberg A (eds): Important Advances in Oncology. Philadelphia, Lippincott. 1985. pp 193-217.
25. Fornara P, Sturm W, Fabricius PG, Schmiedt E: Klinische Relevanz der radioimmunologischen Bestimmung des prostataspezifischen Antigens beim Prostatakarzinom. Urologe [A] 1987:26:158-161.